NCT04975698 2026-03-25
BMTCTN1903
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
Clinical Trials
6 trialsNCT05907759 2026-03-18
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05544019 2026-02-13
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
Phase 1 Recruiting
NCT03038672 2025-11-10
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06343311 2025-08-07
STARLIGHT-1
Estrella Immunopharma, Inc.
Phase 1/2 Recruiting
NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting